Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about SCAP: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | SCAP |
| Key Genes/Proteins | FAM134B, INSIG1, NLRP3, NR1H3 |
| Related Diseases | Fatty Liver Disease |
| Related Pathways | autophagy pathway, lipid metabolism, pyroptosis, Smaild Pathway |
| Linked Hypotheses | 2 hypotheses |
Knowledge base pages for this entity
graph TD
SCAP[SCAP]
SCAP -->|regulates| SREBF[SREBF]
SCAP -->|interacts| SREBP2[SREBP2]
SCAP -->|involved_in| Lysosomal_Degradation[Lysosomal Degradation]
SCAP -->|target for| Fatty_Liver_Disease[Fatty Liver Disease]
SCAP -->|activates| STING[STING]
SCAP -->|interacts| SREBF2[SREBF2]
SCAP -->|activates| SREBF1[SREBF1]
SCAP -->|interacts| SQSTM1[SQSTM1]
lycorine[lycorine] -->|interacts| SCAP
SQSTM1 -->|interacts| SCAP
Lycorine[Lycorine] -->|binds| SCAP
Smaild_Pathway[Smaild Pathway] -->|mediates| SCAP
NLRP3[NLRP3] -->|activates| SCAP
NR1H3[NR1H3] -->|activates| SCAP
FAM134B[FAM134B] -->|regulates| SCAP| Target | Relation | Type | Str |
|---|---|---|---|
| benchmark_ot_ad_answer_key:SCAP | data_in | dataset_row | 0.00 |
| SREBF | regulates | protein | 0.95 |
| SREBP2 | interacts_with | protein | 0.90 |
| Lysosomal Degradation | involved_in | process | 0.85 |
| Fatty Liver Disease | therapeutic_target | disease | 0.80 |
| STING | activates | gene | 0.70 |
| STING | associated_with | gene | 0.60 |
| STING | interacts_with | gene | 0.60 |
| SREBP2 | activates | gene | 0.60 |
| pyroptosis | participates_in | pathway | 0.60 |
| SREBP2 | regulates | gene | 0.60 |
| oligodendrocytes | expressed_in | cell_type | 0.60 |
| SREBF2 | interacts_with | gene | 0.60 |
| autophagy pathway | participates_in | pathway | 0.60 |
| SREBP2 | associated_with | gene | 0.60 |
| lipid metabolism | participates_in | pathway | 0.60 |
| SREBF1 | activates | gene | 0.60 |
| SQSTM1 | associated_with | gene | 0.60 |
| SQSTM1 | interacts_with | gene | 0.60 |
| macrophages | expressed_in | cell_type | 0.55 |
| Source | Relation | Type | Str |
|---|---|---|---|
| benchmark_ot_ad_answer_key:SCAP | data_in | dataset_row | 0.00 |
| lycorine | interacts_with | drug | 0.90 |
| lycorine | inhibits | drug | 0.90 |
| SQSTM1 | interacts_with | protein | 0.90 |
| Lycorine | binds | compound | 0.90 |
| Lycorine | degrades | compound | 0.90 |
| Smaild Pathway | mediates | pathway | 0.80 |
| INSIG1 | activates | gene | 0.60 |
| NLRP3 | activates | gene | 0.60 |
| NLRP3 | interacts_with | gene | 0.60 |
| NR1H3 | activates | gene | 0.60 |
| FAM134B | regulates | gene | 0.60 |
| FAM134B | activates | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning SCAP in their description or question text
Score: 0.626 · neurodegeneration · 2026-04-28
PD genetic aging variants accelerating cell-type-specific epigenetic clock trajectories should produce a measurable prox
Score: 0.612 · neurodegeneration · 2026-04-28
The question is likely underpowered or misleading unless analyses preserve the key strata: PD-. Averaging across these s
Score: 0.608 · neurodegeneration · 2026-04-28
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro
Score: 0.590 · neurodegeneration · 2026-04-25
This is best treated as a stratification and response-modifier hypothesis rather than a primary C1q mechanism. APOE4 may
Score: 0.518 · neuropharmacology · 2026-04-26
The LRP1-Mediated Endosomal Escape Enhancement Strategy proposes that therapeutic antibody delivery to the CNS can be op
Score: 0.420 · molecular-biology · 2026-04-24
A more conjectural model is that APOE4-driven lipid remodeling changes ER membrane organization so that SCAP perceives c
Score: 0.380 · neuropharmacology · 2026-04-27
This strategy combines LDLR upregulation in brain endothelial cells with engineered LRP1-targeting antibodies containing
Score: 0.000 · neuropharmacology · 2026-04-28
This strategy combines targeted upregulation of LDLR expression in brain endothelial cells with engineered antibodies de
Score: 0.000 · alzheimers · 2026-04-28
Mechanistic rationale: Following endocytosis, tau seeds must escape from endosomes to the cytoplasm where they can templ